Objective To identify serum diagnosis or progression biomarkers in patients with lung cancer using protein chip profiling analysis. Method Profiling analysis was performed on 450 sera collected from 213 patients with ...Objective To identify serum diagnosis or progression biomarkers in patients with lung cancer using protein chip profiling analysis. Method Profiling analysis was performed on 450 sera collected from 213 patients with lung cancer, 19 with pneumonia, 16 with pulmonary tuberculosis, 65 with laryngeal carcinoma, 55 with laryngopharyngeal carcinoma patients, and 82 normal individuals. A new strategy was developed to identify the biomarkers on chip by trypsin pre-digestion. Results Profiling analysis demonstrated that an 11.6kDa protein was significandy elevated in lung cancer patients, compared with the control groups （P〈0.001）. The level and percentage of 11.6kDa protein progressively increased with the clinical stages Ⅰ-Ⅳ and were also higher in patients with squamous cell carcinoma than in other subtypes. This biomarker could be decreased after operation or chemotherapy. On the other hand, 11.6kDa protein was also increased in 50% benign diseases of lung and 13% of other cancer controls. After trypsin pre-digestion, a set of new peptide biomarkers was noticed to appear only in the samples containing a 11.6kDa peak. Further identification showed that 2177Da was a fragment of serum amyloid A （SAA, MW 11.6kDa）. Two of the new peaks, 1550Da and 1611Da, were defined from the same protein by database searching. This result was further confirmed by partial purification of 11.6kDa protein and MS analysis. Conclusion SAA is a useful biomarker to monitor the progression of lung cancer and can directly identify some biomarkers on chip.展开更多
目的探讨原发性肝癌介入治疗围手术期不同中医证型的血清蛋白差异表达,并分析其意义。方法将154例原发性肝癌患者按中医辨证分为肝郁证(37例)、脾虚证(45例)、湿热证(18例)、血瘀证(28例)及阴虚证(26例),应用表面加强激光解析电离化飞...目的探讨原发性肝癌介入治疗围手术期不同中医证型的血清蛋白差异表达,并分析其意义。方法将154例原发性肝癌患者按中医辨证分为肝郁证(37例)、脾虚证(45例)、湿热证(18例)、血瘀证(28例)及阴虚证(26例),应用表面加强激光解析电离化飞行时间质谱法(surface enhanced laser desorption ionization time of flight mass spectrometry,SELDI-TOF-MS)分析其血清蛋白指纹图谱,并结合中医证候特点,探讨肝癌介入治疗围手术期不同中医证型的血清蛋白差异表达。结果介入前1周,M/Z为3392、4970、5911、6200、8575Da的血清蛋白峰在各证型间的表达比较,差异有统计学意义(P<0.05,P<0.01);上述5个差异蛋白峰同时出现于脾虚证和血瘀证中。介入后1周,阴虚证M/Z为8575Da的血清蛋白峰表达下调,差异有统计学意义(P<0.01)。结论肝癌介入治疗围手术期不同证型间出现血清差异蛋白质峰。展开更多
背景与目的肺癌是当今世界上最常见的恶性肿瘤之一,迄今缺乏临床诊断可用的分子标志物。本实验应用SELDI技术寻找肺癌新的血清标志物。方法对227例血清样品(包括146例肺癌、13例肺炎、28例结核性胸膜炎和40例正常人血清样品)进行蛋白质...背景与目的肺癌是当今世界上最常见的恶性肿瘤之一,迄今缺乏临床诊断可用的分子标志物。本实验应用SELDI技术寻找肺癌新的血清标志物。方法对227例血清样品(包括146例肺癌、13例肺炎、28例结核性胸膜炎和40例正常人血清样品)进行蛋白质谱检测。对候选蛋白进行质谱鉴定,并结合免疫共沉淀和ELISA技术筛选出肺癌新的候选标志物。结果通过Biomarker WizardTM软件分析显示13.78kDa、13.90kDa和14.07kDa的蛋白峰在肺癌病人血清样品中明显低于对照组。通过1-D胶分离,质谱鉴定和免疫沉淀分析显示这3个差异蛋白峰为野生型甲状腺运载蛋白(nativeTTR)和它的两个变体(cysTTR and glutTTR)。ELISA和SELDI技术分析上述血清样品均发现TTRs在肺癌血清中的表达下调。结论采用SELDI技术首次筛选并鉴定出TTRs,表明其可能作为肺癌诊断的候选血清标志物。展开更多
基金This work was supported by the National Natural Science Foundation of China (Grant No.30370712)Beijing Key Project (Grant No. 7051002)+1 种基金 Beijing Science Technology Committee Project (No.Y0204002040111)a grant of Majon State Basic Research Program of China (No. 2006CB 910100).
文摘Objective To identify serum diagnosis or progression biomarkers in patients with lung cancer using protein chip profiling analysis. Method Profiling analysis was performed on 450 sera collected from 213 patients with lung cancer, 19 with pneumonia, 16 with pulmonary tuberculosis, 65 with laryngeal carcinoma, 55 with laryngopharyngeal carcinoma patients, and 82 normal individuals. A new strategy was developed to identify the biomarkers on chip by trypsin pre-digestion. Results Profiling analysis demonstrated that an 11.6kDa protein was significandy elevated in lung cancer patients, compared with the control groups （P〈0.001）. The level and percentage of 11.6kDa protein progressively increased with the clinical stages Ⅰ-Ⅳ and were also higher in patients with squamous cell carcinoma than in other subtypes. This biomarker could be decreased after operation or chemotherapy. On the other hand, 11.6kDa protein was also increased in 50% benign diseases of lung and 13% of other cancer controls. After trypsin pre-digestion, a set of new peptide biomarkers was noticed to appear only in the samples containing a 11.6kDa peak. Further identification showed that 2177Da was a fragment of serum amyloid A （SAA, MW 11.6kDa）. Two of the new peaks, 1550Da and 1611Da, were defined from the same protein by database searching. This result was further confirmed by partial purification of 11.6kDa protein and MS analysis. Conclusion SAA is a useful biomarker to monitor the progression of lung cancer and can directly identify some biomarkers on chip.
文摘目的探讨原发性肝癌介入治疗围手术期不同中医证型的血清蛋白差异表达,并分析其意义。方法将154例原发性肝癌患者按中医辨证分为肝郁证(37例)、脾虚证(45例)、湿热证(18例)、血瘀证(28例)及阴虚证(26例),应用表面加强激光解析电离化飞行时间质谱法(surface enhanced laser desorption ionization time of flight mass spectrometry,SELDI-TOF-MS)分析其血清蛋白指纹图谱,并结合中医证候特点,探讨肝癌介入治疗围手术期不同中医证型的血清蛋白差异表达。结果介入前1周,M/Z为3392、4970、5911、6200、8575Da的血清蛋白峰在各证型间的表达比较,差异有统计学意义(P<0.05,P<0.01);上述5个差异蛋白峰同时出现于脾虚证和血瘀证中。介入后1周,阴虚证M/Z为8575Da的血清蛋白峰表达下调,差异有统计学意义(P<0.01)。结论肝癌介入治疗围手术期不同证型间出现血清差异蛋白质峰。
文摘背景与目的肺癌是当今世界上最常见的恶性肿瘤之一,迄今缺乏临床诊断可用的分子标志物。本实验应用SELDI技术寻找肺癌新的血清标志物。方法对227例血清样品(包括146例肺癌、13例肺炎、28例结核性胸膜炎和40例正常人血清样品)进行蛋白质谱检测。对候选蛋白进行质谱鉴定,并结合免疫共沉淀和ELISA技术筛选出肺癌新的候选标志物。结果通过Biomarker WizardTM软件分析显示13.78kDa、13.90kDa和14.07kDa的蛋白峰在肺癌病人血清样品中明显低于对照组。通过1-D胶分离,质谱鉴定和免疫沉淀分析显示这3个差异蛋白峰为野生型甲状腺运载蛋白(nativeTTR)和它的两个变体(cysTTR and glutTTR)。ELISA和SELDI技术分析上述血清样品均发现TTRs在肺癌血清中的表达下调。结论采用SELDI技术首次筛选并鉴定出TTRs,表明其可能作为肺癌诊断的候选血清标志物。
